Cassandra J. Schmitt, PharmD (@cjschmitt2) identifies guideline recommendations for antiplatelet agents following percutaneous coronary intervention (PCI), reviews the literature examining the safety and efficacy of clopidogrel, ticagrelor, and prasugrel and discusses factors that influence the selection of a P2Y12 agent following PCI. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.